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BACKGROUND: It has recently been reported by several sources that original (i.e., present in vivo) glioma cell phenotypes or genotypes
cannot be maintained in vitro. For example, glioblastoma cell lines presenting EGFR amplification cannot be established.
METHODS AND RESULTS: IDH1 sequencing and loss of heterozygosity analysis was performed for 15 surgery samples of astrocytoma and
early and late passages of cells derived from those and for 11 archival samples. We were not able to culture tumour cells presenting
IDH1 mutations originating from currently proceeded 10 tumours; the same results were observed in 7 samples of archival material.
CONCLUSION: The IDH1 mutation is expected to be almost mutually exclusive with EGFR amplification, so glioma cells with IDH1
mutations seem to represent a new group of tumour cells, which cannot be readily analysed in vitro because of their elimination. The
reasons for this intriguing phenomenon should be investigated since its understanding can help to define a new therapeutic approach
based on simulating in vivo conditions, responsible for tumour cells elimination in vitro. Moreover, a new model for culturing glioma
cells in vitro should be designed since the current one does not provide conditions corresponding to in vivo growth.
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The discovery of IDH1 mutations was very significant for neuro-
oncologists. So far, mutations of IDH1 have been detected almost
exclusively in glial tumours (Bleeker et al, 2009), including
astrocytomas and secondary glioblastomas, but not in primary
glioblastomas (Watanabe et al, 2009). In addition, the function of
IDH1 does not seem to be typical for a tumour suppressor, a
classical oncogene, or a mutator. The IDH1 protein is required for
NADPH production and lipid synthesis (Kloosterhof et al, 2011).
All of these factors have attracted a lot of attention to IDH1
analyses, including in vitro investigations. Nevertheless, it appears
difficult to propagate cells showing the IDH1 mutation in vitro
since they are easily eliminated under standard cell culture
conditions.
MATERIALS AND METHODS
Tumour samples
The study included 26 (15 cultured and 11 archival) cases of
astrocytic tumours (17 – diffuse astrocytoma, 9 – anaplastic
astrocytoma) diagnosed at the Department of Pathomorphology,
Medical University of Lodz according to the World Health
Organisation criteria for classification of brain tumours. Tissue
samples were obtained from patients with astrocytic tumours
treated in the Department of Neurosurgery, Medical University of
Lodz, Poland.
Cell cultures/DNA isolation
Fifteen specimens were cultured. The tumour cells were dispersed
by means of collagenase type IV (200Uml
–1,3 7 1C for 6h).
Subsequently, the cells were cultured in alpha MEM media
containing 10% FBS. After 48 and 96h, the medium was changed
and part of the cells was isolated for DNA analysis. DNA was
isolated from snap-frozen tissues (stored at –801C) and from cells
harvested after the first and the second passage. On the first and
the second day, DNA samples were also isolated from cells floating
(dead) in the culture medium for the purpose of the DNA profile
analysis. The first harvesting was performed no longer than 2 days
after cells culturing. For loss of heterozygosity (LOH) analysis,
DNA was isolated from blood samples. All DNA samples were
extracted by means of a Macherey–Nagel DNA purification kit
(Macherey–Nagel, Du ¨ren, Germany). All types of cultured cells,
including floating cells, were tested for Trypan blue absorbing.
Archival sample analysis
Eleven samples of astrocytoma with visible karyotypic changes
(collected in 1990s) were verified for IDH1 mutation presence.
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 801C) and from microscopic specimens derived for karyotyping
from cell cultures after the second passage. All DNA samples were
extracted by means of a Macherey–Nagel DNA purification kit.
IDH1 sequencing
Exon 6, including codon 132 of the IDH1 gene, was amplified by
PCR and sequenced using the dideoxy termination method and
SequiTherm Excel DNA Sequencing Kit (Epicentre Technologies,
Madison, WI, USA). The primers used for PCR amplification of the
DNA sequences were: IDH1 –5 0-GGCACCCATCTTCTGTGTTT-30
(sense) and 50-ATATATGCATTTCTCAATTTCA-30 (antisense). The
sequencing primers used were: IDH1 exon 6 – 50-GCAAAAATATCC
CCCGGCTT-30 (sense), and IDH1 exon 6 – 50-CGGTCTTCAGAGAAG
CCATT-30 (antisense). A Li-Cor automatic sequencer system (Li-Cor,
Lincoln, NE, USA) was applied for the separation and analysis of
PCR-sequencing products.
LOH analysis: microsatellite analysis to classify type of
in vitro surviving cells (normal vs tumour)
The specimens were examined for LOH using pairs of tumour
specimens and corresponding peripheral blood samples. The
markers were selected using the NCBI database (D1S508,
D1S199, D1S197, D1S162, D1S2734, D1S2720, D1S429, D1S510,
D10S1709, D10S209, D10S587, D10S197, D10S1267, D10S587,
D18S481, D22S303, D22S257, D22S1163 and D22S1150) and
obtained from MWG-Biotech AG (Ebersberg, Germany). PCR
products were visualised with a Li-Cor automatic sequencer. Loss
of heterozygosity was judged to be present if the allelic signal
intensity of the tumour sample was reduced by at least 50% relative
to the corresponding allele in the patient’s control DNA.
RESULTS
IDH1 mutations in frozen tumour cells and corresponding
cell cultures
Cell cultures DNA sequencing revealed IDH1 mutations in 10
surgical specimens of astrocytic tumours coming from 15 patients.
The mutated template was no longer detectable in adherent cells
grown in vitro (in four cases after the first passage and in six cases
after the second passage) derived from the tumour samples with
IDH1 mutations (Figure 1). Free floating cells (absorbing Trypan
blue) from the medium showed IDH1 mutation after the first and
the second passage. Our previous investigations showed that none
of the tumours presented EGFR amplification, and three showed
a mutation of TP53.
In eight cases, cell cultures derived from specimens originally
presenting the IDH1 mutation survived at least 10 passages but
were never stabilised. In five of those cases, LOH was observed in
the initial culture. Only in one case, tumour cells presenting LOH
were observed after disappearance of cells presenting IDH1
mutation. It suggested that after elimination of cells with IDH1
mutation only normal cells remained in the majority of the cell
cultures. Two out of five astrocytomas presenting lack of IDH1
mutation (after the analysis of surgery sample and early cell
culture sample), showed LOH of several markers. Cells coming
from one of them cultured in standard cell culture conditions still
show LOH of 1p (after 20 passages – possible stabilisation). In the
second case, we did not detect in the standard cell culture
conditions LOH observed in vivo.
Archival sample analysis In all, 7 out of 11 DNA samples isolated
from frozen tumour tissues showed IDH1 mutations in the
sequencing analysis. The quality and amount of archival DNA
was not sufficient to perform other molecular analyses such as
LOH, and so on. Nonetheless, in six corresponding DNA samples
isolated from cultured cells in 1990s after the second passage, IDH1
mutation was not visible. In one remaining case, mutated bands
were significantly weaker (almost invisible) than in the frozen
tissue samples.
DISCUSSION
IDH1 mutations seem to have a significant role in glial tumours
(Ducray et al, 2009; Hartmann et al, 2009). Zhao et al (2009)
showed that IDH1 regulates HIF1 expression. Recently, Sanson
et al (2009) suggested that the IDH1 mutation might correlate with
a glial tumour grade. However, the specific role of the IDH1
mutation in glial tumours, such as astrocytic tumours and
secondary glioblastomas is unknown.
In this paper, we described obstacles in culturing glioma cells
with IDH1 mutations. What needs to be added, similar problems
were described for EGFR amplification analysis in glioblastomas,
that is, disappearance of EGFR amplification was observed in
standard cell culture conditions. Elimination of EGFR amplifica-
tion during glioblastoma cells culturing is a well-known phenom-
enon the causes of which, however, remain enigmatic (Pandita
et al, 2004; Witusik-Perkowska et al, 2010). We observed two cases
of astrocytoma without IDH1 mutation presenting LOH for several
markers in surgery samples (in vivo). In vitro proliferating
(surviving) cells of one of them showed lack of LOH (putative
normal) whereas cells of the second astrocytoma presenting LOH
survived in standard cell culture conditions for 20 passages so far.
In addition, glioma cell culture collections can be analysed, and
none of the 15 commercially available cell lines presents IDH1
mutation (Bleeker et al, 2009; Kloosterhof et al, 2011).
ACGT ACGT ACGT ACGT
G59 G60
1 2 1 2
Figure 1 IDH1 gene sequencing analysis of two astrocytic tumours (G59
and G60). The analysis of DNA from frozen samples shows a heterozygous
mutation; both mutated and wild-type nucleotides are detected (1). The
analysis of the second passage of corresponding culture cells shows the lack
(G59), or almost invisible band (G60) of the mutated nucleotide (2).
Mutated nucleotides are marked with arrows.
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mutation cannot be propagated in vitro in conditions suitable for
survival of normal human cells or glioma cells without IDH1
mutation. The IDH1 mutation is expected to be almost mutually
exclusive with EGFR amplification, so glioma cells with IDH1
mutation seem to represent a new group of tumour cells, which
cannot be readily analysed in vitro because of their elimination.
Nonetheless, we do not suggest that IDH1 mutation is responsible
for cells in vitro elimination. Apparently, the presence of a TP53
mutation does not protect glioma cells with IDH1 mutation against
factors responsible for cells elimination. Although we did not
define that beyond any doubt, the cells that survived after the
elimination of tumour cells with IDH1 mutation are most likely
normal cells. Surprisingly, the kind of cells surviving in vitro in
case of gliomas presenting EGFR amplification has not been
defined in spite of years of investigation. We did not detect genetic
alterations in cells cultured after the elimination of cells showing
IDH1 mutation, except for one case. Moreover, IDH1 mutation is
probably the earliest stage of glioma tumourigenesis (Kloosterhof
et al, 2011).
Defining cell culture conditions that would sustain the
original phenotype and genotype of glioma cells is critical. The
cell culture conditions currently used are artificial and thus
unsuitable for the growth and analysis of glioma cells – causing
numerous artefacts. Nonetheless, as normal cells seem to be more
congruous to the standard cell culture conditions than glioma cells
with IDH1 mutation, the factors responsible for the elimination
of glioma cells in vitro should be identified for possible
pharmacological use.
ACKNOWLEDGEMENTS
The presented study was supported by the Ministry of Science and
Higher Education, Poland, Grant no. NN401 1558 331558.
REFERENCES
Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP,
Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A,
Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A (2009) IDH1
mutations at residue p.R132 (IDH1(R132)) occur frequently in high-
grade gliomas but not in other solid tumours. Hum Mutat 30: 7–11
Ducray F, Marie Y, Sanson M (2009) IDH1 and IDH2 mutations in gliomas.
N Engl J Med 360: 2248–2249
Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J,
Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A,
Jeuken JW, Wesseling P, Reifenberger G, von Deimling A (2009) Type and
frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1010 diffuse gliomas.
Acta Neuropathol 118: 469–474
Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ
(2011) Isocitrate dehydrogenase-1 mutations: a fundamentally new
understanding of diffuse glioma? Lancet Oncol 12: 83–91
Pandita A, Aldape KD, Zadeh G, Guha A, James CD (2004) Contrasting in
vivo and in vitro fates of glioblastoma cell subpopulations with amplified
EGFR. Genes Chromosomes Cancer 39: 29–36
Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F,
Hallani SE, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY
(2009) Isocitrate dehydrogenase 1 codon 132 mutation is an
important prognostic biomarker in gliomas. J Clin Oncol 27:
4150–4154
Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are
early events in the development of astrocytomas and oligodendro-
gliomas. Am J Pathol 174: 1149–1153
Witusik-Perkowska M, Rieske P, Hulas-Bigoszewska K, Zakrzewska M,
Stawski R, Kulczycka-Wojdala D, Bienkowski M, Stoczynska-
Fidelus E, Gresner SM, Piaskowski S, Jaskolski DJ, Papierz W,
Zakrzewski K, Kolasa M, Ironside JW, Liberski PP (2010) Glio-
blastoma-derived spheroid cultures as an experimental model
for analysis of EGFR anomalies. J Neurooncol 2010 (E-pub ahead of
print 29 August 2010; doi:10.1007/s11060-010-0352-0)
Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z, Gong L, Peng Y,
Ding J, Lei Q, Guan KL, Xiong Y (2009) Glioma-derived mutations in
IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha.
Science 324: 261–265
EGFR phenomenon repeated in IDH1
S Piaskowski et al
970
British Journal of Cancer (2011) 104(6), 968–970 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s